Anatoli S. Gleiberman

Anatoli S. Gleiberman

Auto-generated profile, based on publicly available information

Anatoli S. Gleiberman

Genome Protection, Inc

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
KNKsenia A. Novototskaya-Vlasova
Ksenia A. Novototskaya-Vlasova
NNNickolay S. Neznanov
Nickolay S. Neznanov
IMIvan Molodtsov
Ivan Molodtsov
BHBrandon M. Hall
Brandon M. Hall
MCMairead Commane
Mairead Commane
MGMarina Antoch and Andrei Gudkov
Marina Antoch and Andrei Gudkov
Activation of endogenous retrotransposons frequently occurs in cancer cells and contributes to tumor genomic instability. To test whether inhibition of retrotranspositions has an anticancer effect, we used treatment with the nucleoside reverse transcriptase inhibitor (NRTI) stavudine (STV) in mouse cancer models, MMTV-HER2/Neu and Th-MYCN, that spontaneously develop breast cancer and neuroblastoma, respectively. In both cases, STV in drinking water did not affect tumor incidence nor demonstrate direct antitumor effects. However, STV dramatically extended progression-free survival in both models following an initial complete response to chemotherapy. To approach the mechanism underlying this phenomenon, we analyzed the effect of NRTI on the selection of treatment-resistant variants in tumor cells in culture. Cultivation of mouse breast carcinoma 4T1 in the presence of STV dramatically reduced the frequency of cells capable of surviving treatment with anticancer drugs. Global transcriptome analysis demonstrated that the acquisition of drug resistance by 4T1 cells was accompanied by an increase in the constitutive activity of interferon type I and NF-κB pathways and an elevated expression of LINE-1 elements, which are known to induce inflammatory responses via their products of reverse transcription. Treatment with NRTI reduced NF-κB activity and reverted drug resistance. Furthermore, the inducible expression of LINE-1 stimulated inflammatory response and increased the frequency of drug-resistant variants in a tumor cell population. These results indicate a mechanism by which retrotransposon desilencing can stimulate tumor cell survival during treatment and suggest reverse transcriptase inhibition as a potential therapeutic approach for targeting the development of drug-resistant cancers.

8 November 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
AVAlexandra V. Vylegzhanina
Alexandra V. Vylegzhanina
IBIvan A. Bespalov
Ivan A. Bespalov
KNKsenia A. Novototskaya-Vlasova
Ksenia A. Novototskaya-Vlasova
BHBrandon M. Hall
Brandon M. Hall
AGAnatoli S. Gleiberman
Anatoli S. Gleiberman
MGMarina Antoch and Andrei Gudkov
Marina Antoch and Andrei Gudkov
Long interspersed nuclear element-1 (LINE-1 or L1), the most abundant family of autonomous retrotransposons occupying over 17% of human DNA, is epigenetically silenced in normal tissues by the mechanisms involving p53 but is frequently derepressed in cancer, suggesting that L1-encoded proteins may act as tumor-associated antigens recognized by the immune system. In this study, we established an immunoassay to detect circulating autoantibodies against L1 proteins in human blood. Using this assay in >2,800 individuals with or without cancer, we observed significantly higher IgG titers against L1-encoded ORF1p and ORF2p in patients with lung, pancreatic, ovarian, esophageal, and liver cancers than in healthy individuals. Remarkably, elevated levels of anti–ORF1p-reactive IgG were observed in patients with cancer with disease stages 1 and 2, indicating that the immune response to L1 antigens can occur in the early phases of carcinogenesis. We concluded that the antibody response against L1 antigens could contribute to the diagnosis and determination of immunoreactivity of tumors among cancer types that frequently escape early detection. Significance: The discovery of autoantibodies against antigens encoded by L1 retrotransposons in patients with five poorly curable cancer types has potential implications for the detection of an ongoing carcinogenic process and tumor immunoreactivity.

1 March 2004 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
CCCatherine Carrière
Catherine Carrière
AGAnatoli Gleiberman
Anatoli Gleiberman
CLChijen R. Lin
Chijen R. Lin
MRMichael G. Rosenfeld
Michael G. Rosenfeld

2 June 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RPRuby Pandher
Ruby Pandher
CXChengyuan Xue
Chengyuan Xue
LGLaura Gamble
Laura Gamble
GMGiorgio Milazzo
Giorgio Milazzo
SGSimone Di Giacomo
Simone Di Giacomo
MNMurray Norris
Murray Norris
Despite Myc oncoproteins being major causal factors in human cancer, they remain “undruggable.” The MYCN oncogene is one of the most powerful prognostic markers for the childhood cancer neuroblastoma and represents an important target for developing novel therapeutics. Here, we report the finding and characterization of M606, a selective small molecule inhibitor of MYCN, which was identified by screening a diverse chemical library. M606 reduced MYCN protein levels in neuroblastoma cell lines and upregulated hypoxia-inducible factor 1 alpha (HIF1A). Using siRNA-mediated knockdown of MYCN , c-Myc , or HIF1A in HepG2 and BE(2)-C cells followed by M606 treatment, we demonstrated that Myc downregulation and HIF1A upregulation were two independent effects of M606 treatment. M606 selectively targeted neuroblastoma cell lines expressing higher levels of MYCN protein and delayed neuroblastoma development in the TH-MYCN transgenic mouse model. Metabolomic analysis showed that M606 modulated glucose metabolism, consistent with a hypoxic response and iron deprivation. Biochemical characterization of M606 not only confirmed its iron-chelating properties but also revealed its ability to downregulate MYCN promoter activity, which could be rescued by the addition of iron. Luciferase assays identified the minimal MYCN promoter region required for the M606 response, which contained overlapping E2F transcription factor binding sites. Further evaluation defined a key role for E2F3 in the M606-mediated response. The finding of a potent cell-permeable iron chelator that can chelate iron to directly downregulate MYCN transcription via an E2F3-mediated response represents a potentially valuable therapeutic approach in the treatment of cancers overexpressing Myc oncoproteins.

18 July 2022 in Research Square
Verified
Preprint
Open access
PDF file
KLKaterina Leonova
Katerina Leonova
IGIlya Gitlin
Ilya Gitlin
AGAnatoli Gleiberman
Anatoli Gleiberman
ITIlia Toshkov
Ilia Toshkov
NTNicholas Trageser
Nicholas Trageser
MGMarina Antoch and Andrei Gudkov
Marina Antoch and Andrei Gudkov
Systemic genotoxic stress is expected to generate senescent cells and accelerate aging. Surprisingly, mice subjected to lethal dose of total body irradiation and rescued by bone marrow transplantation (TBIBMT) showed neither gain of aging-related frailty nor increase in senescence markers. Mesenchymal cells in various tissues of TBIBMT mice do not undergo senescence and stay dormant with unrepaired DNA breaks during the entire life of the animal and activate senescence program only after they are forced into cell divisions ex vivo or in vivo. Accumulation of such dormant senescence-prone cells (DSPC) has no physiological effects under normal life conditions but is associated with impaired wound healing, decelerated tumor growth due to inefficient scaring and stroma formation and rapid increase in frailty and death after placement on a high-fat diet suggesting the involvement of DSPC accumulation in obesity-induced health decline in cancer survivors following genotoxic treatments.

26 May 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
NFNatalia Fedtsova
Natalia Fedtsova
EKElena A. Komarova
Elena A. Komarova
KGKellee F. Greene
Kellee F. Greene
LNLiliya R. Novototskaya
Liliya R. Novototskaya
IMIvan Molodtsov
Ivan Molodtsov
MGMarina Antoch and Andrei Gudkov
Marina Antoch and Andrei Gudkov
Transplantation of bone marrow (BM) is made possible by the differential sensitivity of its stromal and hematopoietic components to preconditioning by radiation and/or chemotherapeutic drugs. These genotoxic treatments eliminate host hematopoietic precursors by inducing p53-mediated apoptosis but keep the stromal niche sufficiently intact for the engraftment of donor hematopoietic cells. We found that p53-null mice cannot be rescued by BM transplantation (BMT) from even the lowest lethal dose of total body irradiation (TBI). We compared structural changes in BM stroma of mice differing in their p53 status to understand why donor BM failed to engraft in the irradiated p53-null mice. Irradiation did not affect the general structural integrity of BM stroma and induced massive expression of alpha-smooth muscle actin in mesenchymal cells followed by increased adiposity in p53 wild-type mice. In contrast, none of these events were found in p53-null mice, whose BM stroma underwent global structural damage following TBI. Similar differences in response to radiation were observed in in vitro-grown bone-adherent mesenchymal cells (BAMC): p53-null cells underwent mitotic catastrophe while p53 wild-type cells stayed arrested but viable. Supplementation with intact BAMC of either genotype enabled donor BM engraftment and significantly extended longevity of irradiated p53-null mice. Thus, successful preconditioning depends on the p53-mediated protection of cells critical for the functionality of BM stroma. Overall, this study reveals a dual positive role of p53 in BMT: it drives apoptotic death of hematopoietic cells and protects BM stromal cells essential for its functionality.